{
  "docId": "019de073-ec7b-760b-b9a4-60ceb97e90d9",
  "docSlug": "fef1528177829f37cded553f72a56b72",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 44 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 44,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "Includes detailed footnotes explaining segment reclassifications and definitions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ec7b-760b-b9a4-60ceb97e90d9/5",
  "deckHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9",
  "deckJsonHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9.json",
  "deckAnchorHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.38,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Core EPS YTD 2021 vs 2022",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "606525d7-d5cb-4eea-8e51-bf79fbdc57ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Total Revenue YTD 2021 vs 2022",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d23efa6a-b40b-459e-9a86-d8235bb303e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "1. In FY 2022, Total Revenue from Koselugo is included in Rare Disease...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee1ef366-176f-448d-810a-c450ae74f956",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "list",
      "text": "Revenue breakdown by segment: Oncology, BioPharmaceuticals (CVRM, R&I, V&I), Rare Disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd450a95-beef-493b-b122-59be577de6b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "Upgraded 2022 guidance (CER) : Core EPS to increase by high twenties to low thirties %, dependent on collaboration milestones and Evusheld deliveries",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c357b8c-6c3b-48b3-a97b-71caf4d92e21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Robust, broad-based performance supports FY 2022 Core EPS guidance upgrade",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10d4a31a-ebbe-4ba1-853d-ae08ea89a294",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "YTD and Q3 2022 Results: key updates",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82760130-afbb-4efe-8e9d-7442bf821ea4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "10cb02c5-e89d-455a-a3a5-e90ba21ea43b",
      "evidence": "Robust, broad-based performance supports FY 2022 Core EPS guidance upgrade",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "action-titles",
      "slug": null,
      "matchId": "560af5e0-f57e-435d-8e30-9637fca86c37",
      "evidence": "The slide uses a thesis-driven headline to summarize the key takeaway.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "5ce88c11-4cfa-464b-83ff-6894b3a1edcd",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Attention",
      "beatSlug": "monroes-sequence-attention",
      "evidence": "Slides 1-5 provide an overview of the presentation and key updates.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}